FdaApplication
NDA 215866
Identifiers
- fda_app_no: NDA215866
Properties
| Property | Value |
|---|---|
| applicant_name | ELI LILLY AND CO |
| application_type | NDA |
| approval_date | 2022-05-13 |
Revenue by product
MOUNJARO
| Period | Revenue |
|---|---|
| Q2 2026 | $9.9B |
| Q1 2026 | $8.7B |
| Q4 2025 | $7.4B |
| Q3 2025 | $6.5B |
| Q2 2025 | $5.2B |
| Q1 2025 | $3.8B |
| Q4 2024 | $7.1B |
| Q3 2024 | $6.2B |
| Q2 2024 | $6.2B |
| Q1 2024 | $3.6B |
| Q4 2023 | $2.2B |
| Q3 2023 | $1.4B |
| Q2 2023 | $979.7M |
| Q1 2023 | $568.5M |
| Q4 2022 | $279.3M |
| Q3 2022 | $187.3M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
MOUNJARO (AUTOINJECTOR)
| Period | Revenue |
|---|---|
| Q2 2026 | $9.9B |
| Q1 2026 | $8.7B |
| Q4 2025 | $7.4B |
| Q3 2025 | $6.5B |
| Q2 2025 | $5.2B |
| Q1 2025 | $3.8B |
| Q4 2024 | $7.1B |
| Q3 2024 | $6.2B |
| Q2 2024 | $6.2B |
| Q1 2024 | $3.6B |
| Q4 2023 | $2.2B |
| Q3 2023 | $1.4B |
| Q2 2023 | $979.7M |
| Q1 2023 | $568.5M |
| Q4 2022 | $279.3M |
| Q3 2022 | $187.3M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (24)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| MOUNJARO | TIRZEPATIDE | 5MG/0.5ML (5MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO | TIRZEPATIDE | 40MG/2.4ML (16.7MG/ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO | TIRZEPATIDE | 20MG/2.4ML (8.33MG/ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO | TIRZEPATIDE | 10MG/2.4ML (4.17MG/ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO | TIRZEPATIDE | 50MG/2.4ML (20.8MG/ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO | TIRZEPATIDE | 2.5MG/0.5ML (2.5MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO | TIRZEPATIDE | 30MG/2.4ML (12.5MG/ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO | TIRZEPATIDE | 12.5MG/0.5ML (12.5MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO | TIRZEPATIDE | 60MG/2.4ML (25MG/ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO | TIRZEPATIDE | 15MG/0.5ML (15MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO | TIRZEPATIDE | 7.5MG/0.5ML (7.5MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO | TIRZEPATIDE | 10MG/0.5ML (10MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO (AUTOINJECTOR) | TIRZEPATIDE | 7.5MG/0.5ML (7.5MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO (AUTOINJECTOR) | TIRZEPATIDE | 5MG/0.5ML (5MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO (AUTOINJECTOR) | TIRZEPATIDE | 2.5MG/0.5ML (2.5MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO (AUTOINJECTOR) | TIRZEPATIDE | 10MG/0.5ML (10MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO (AUTOINJECTOR) | TIRZEPATIDE | 12.5MG/0.5ML (12.5MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO (AUTOINJECTOR) | TIRZEPATIDE | 15MG/0.5ML (15MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO KWIKPEN | TIRZEPATIDE | 10MG/2.4ML (4.17MG/ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO KWIKPEN | TIRZEPATIDE | 50MG/2.4ML (20.8MG/ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO KWIKPEN | TIRZEPATIDE | 30MG/2.4ML (12.5MG/ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO KWIKPEN | TIRZEPATIDE | 60MG/2.4ML (25MG/ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO KWIKPEN | TIRZEPATIDE | 20MG/2.4ML (8.33MG/ML) | SOLUTION;SUBCUTANEOUS |
| MOUNJARO KWIKPEN | TIRZEPATIDE | 40MG/2.4ML (16.7MG/ML) | SOLUTION;SUBCUTANEOUS |
24 products